HIGHLIGHTS
- who: Glucose transporter type et al. from the ETHICAL APPROVAL Ethics committee approval for our study was obtained from the ethics committee of the Recep Tayyip Erdogan University Faculty of Medicine, non-interventional clinical research (E-4046558705001.04-352). The study was conducted in accordance with the Declaration of Helsinki, the ethical standards of the institutional research committee, and the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guideline19. have published the Article: Predicting response to neoadjuvant therapy with glucose transporter-1 in breast cancer, in the Journal: (JOURNAL)
- what: The authors aimed to investigate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.